---
title: "BlossomHill closes up 18% on strongest day since August IPO"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299233306.md"
description: "BlossomHill Therapeutics (BLSM) shares surged over 18% on Wednesday, marking its strongest single-day performance since its August IPO. The rally followed the release of updated Phase 1/2 SOLARA trial data for lead drug BH-30643 in EGFR-mutant non-small cell lung cancer. Results showed a 45% objective response rate and 88% disease control rate among patients with specific resistance mutations, highlighting the drug's potential to overcome limitations of current EGFR inhibitors."
datetime: "2026-09-16T20:45:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299233306.md)
  - [en](https://longbridge.com/en/news/299233306.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299233306.md)
generator: "portal-rs"
---

# BlossomHill closes up 18% on strongest day since August IPO


### Related Stocks

- [BLSM.US](https://longbridge.com/en/quote/BLSM.US.md)

## Related News & Research

- [BlossomHill Therapeutics to present updated Phase 1/2 SOLARA trial data on BH-30643 in EGFR-mutant NSCLC at WCLC 2026](https://longbridge.com/en/news/297641175.md)
- [BlossomHill reports 45% ORR, 88% DCR for BH-30643 in C797S-positive NSCLC; Phase 2 planned](https://longbridge.com/en/news/299043586.md)
- [BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) Sees Significant Increase in Short Interest](https://longbridge.com/en/news/301514983.md)
- [Rocket Lab Just Had Another Setback. Here’s Why I’m Finally Buying the Stock Anyway](https://longbridge.com/en/news/302545565.md)
- [SpaceX Bulls Get Louder After Q3 Earnings Print, But One Firm Flags $475B Funding Gap](https://longbridge.com/en/news/302596793.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**